ReviewHypertension research : official journal of the Japanese Society of Hypertension2022
Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06130046 (MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
Who cites it
31 citing papers in PubMed, 38 citations in OpenAlex.
- Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial.Viruses · 2025Trial
- Adipocyte-specific deletion of adrenomedullin exacerbates high-fat diet-induced hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Characterizing the molecular landscape of venous congestion.World journal of critical care medicine · 2026Article
- Cardiovascular Diseases: Exploring Epidemiology, Pathophysiology, Risk Factors, and Medicinal Plant-Based Therapies: A Narrative Review.Health science reports · 2026Article
- Prognostic value and organ-specific correlations of admission MR-proADM in critically ill patients: a retrospective exploratory study.Journal of anesthesia, analgesia and critical care · 2026Article
- Elevated Serum Proadrenomedullin Levels in Rheumatoid Arthritis Versus Spondyloarthritis: Insights From a Biobank Cohort.ACR open rheumatology · 2026Article
- Rational design of k-casein peptides to modulate GSK-3B dynamics for Alzheimer's therapy.Scientific reports · 2026Article
- Sensory impairments and epigenetic aging: insights from self-rated hearing and vision in United States adults.GeroScience · 2026Article
- Rapid responses of catecholamines, natriuretic peptides and inflammatory markers to acute type B aortic dissection (NeuroendOcrine horMone release in acute type b Aortic Dissection [NOMAD] Study).JVS-vascular science · 2026Article
- In Vitro and In Vivo Characterization of 40 kDa PEGylated Adrenomedullin in a DSS-Induced Colitis Model.International journal of molecular sciences · 2025Article
- Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly-A Preliminary Study.Biomedicines · 2025Article
- Enhancing Stability and Bioavailability of Peptidylglycine Alpha-Amidating Monooxygenase in Circulation for Clinical Use.Biomolecules · 2025Article
- Pro-adrenomedullin associates with congestion in acute heart failure patients.ESC heart failure · 2024Article
- Angiogenesis and multiple myeloma: Exploring prognostic potential of adrenomedullin.Cancer medicine · 2024Article
- The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature.Journal of clinical medicine · 2024Review
- Effect of adrenomedullin on obesity-related hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Review
- Single-Cell Analyses Offer Insights into the Different Remodeling Programs of Arteries and Veins.Cells · 2024Article
- Mid-Regional Pro-Adrenomedullin Can Predict Organ Failure and Prognosis in Sepsis?International journal of molecular sciences · 2023Article
- Plasma Protein Profiling of Incident Cardiovascular Diseases: A Multisample Evaluation.Circulation. Genomic and precision medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenomedullin (AM) is a vasodilative peptide with various physiological functions, including the maintenance of vascular tone and endothelial barrier function. AM levels are markedly increased during severe inflammation, such as that associated with sepsis; thus, AM is expected to be a useful clinical marker and therapeutic agent for inflammation. However, as the increase in AM levels in cardiovascular diseases (CVDs) is relatively low compared to that in infectious diseases, the value of AM as a marker of CVDs seems to be less important. Limitations pertaining to the administrative route and short half-life of AM in the bloodstream (<30 min) restrict the therapeutic applications of AM for CVDs. In early human studies, various applications of AM for CVDs were attempted, including for heart failure, myocardial infarction, pulmonary hypertension, and peripheral artery disease; however, none achieved success. We have developed AM as a therapeutic agent for inflammatory bowel disease in which the vasodilatory effect of AM is minimized. A clinical trial evaluating this AM formulation for acute cerebral infarction is ongoing. We have also developed AM derivatives that exhibit a longer half-life and less vasodilative activity. These AM derivatives can be administered by subcutaneous injection at long-term intervals. Accordingly, these derivatives will reduce the inconvenience in use compared to that for native AM and expand the possible applications of AM for treating CVDs. In this review, we present the latest translational status of AM and its derivatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.